Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/50275
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- INI - Artigos de Periódicos [3516]
Metadata
Mostrar registro completo
CLINICAL PROFILE AND MORTALITY IN PATIENTS WITH T. CRUZI/HIV CO-INFECTION FROM THE MULTICENTER DATA BASE OF THE "NETWORK FOR HEALTHCARE AND STUDY OF TRYPANOSOMA CRUZI/HIV CO-INFECTION AND OTHER IMMUNOSUPPRESSION CONDITIONS"
HIV diagnosis and management
Trypanosoma cruzi
Meningoencephalitis
Antiparasitic therapy
Parasitic diseases
HIV infections
Chagas disease
Autor(es)
Shikanai-Yasuda, Maria Aparecida
Mediano, Mauro Felippe Felix
Novaes, Christina Terra Gallafrio
Sousa, Andréa Silvestre de
Sartori, Ana Marli Christovam
Santana, Rodrigo Carvalho
Correia, Dalmo
Castro, Cleudson Nery de
Severo, Marilia Maria dos Santos
Hasslocher-Moreno, Alejandro Marcel
Fernandez, Marisa Liliana
Salvador, Fernando
Pinazo, Maria Jesús
Bolella, Valdes Roberto
Furtado, Pedro Carvalho
Corti, Marcelo
Pinto, Ana Yecê Neves
Fica, Alberto
Molina, Israel
Gascon, Joaquim
Viñas, Pedro Albajar
Cortez-Escalante, Juan
Ramos Jr, Alberto Novaes
Almeida, Eros Antonio de
Mediano, Mauro Felippe Felix
Novaes, Christina Terra Gallafrio
Sousa, Andréa Silvestre de
Sartori, Ana Marli Christovam
Santana, Rodrigo Carvalho
Correia, Dalmo
Castro, Cleudson Nery de
Severo, Marilia Maria dos Santos
Hasslocher-Moreno, Alejandro Marcel
Fernandez, Marisa Liliana
Salvador, Fernando
Pinazo, Maria Jesús
Bolella, Valdes Roberto
Furtado, Pedro Carvalho
Corti, Marcelo
Pinto, Ana Yecê Neves
Fica, Alberto
Molina, Israel
Gascon, Joaquim
Viñas, Pedro Albajar
Cortez-Escalante, Juan
Ramos Jr, Alberto Novaes
Almeida, Eros Antonio de
Afiliação
University of São Paulo. Faculdade de Medicina. Departament of Infectious and Parasitic. São Paulo, SP, Brazil / University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Laboratory of Immunology. São Paulo, SP, Brazil / WHO Technical Group IVb on prevention, control and management of non congenital infections of the Global Network for Chagas Disease Elimination. Geneva, Switzerland.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Division of Infectious Diseases. São Paulo, SP, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Division of Infectious Diseases. São Paulo, SP, Brazil.
Ribeirão Preto Medical School University of São Paulo. Department of Internal Medicine. Division of Infectious Diseases. Ribeirão Preto, SP, Brazil.
Federal University of Triângulo Mineiro. Department of Internal Medicine. Discipline of Infectious and Parasitic Diseases. Uberaba, MG, Brazil.
University of Brasilia. School of Medicine. Centre for Tropical Medicine. Brasília, DF, Brazil.
Federal University of Health Sciences of Porto Alegre. Porto Alegre, RS, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Hospital de Infecciosas. Buenos Aires, Argentina / Health Ministry. National Institute of Parasitology. Departament of Clinics, Pathology and Treatment. Buenos Aires, Argentina.
Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital. Department of Infectious Diseases. Barcelona, Spain.
ISGlobal. Universitat de Barcelona. Hospital Clínic. Barcelona, Spain.
Ribeirão Preto Medical School University of São Paulo. Department of Internal Medicine. Division of Infectious Diseases. Ribeirão Preto, SP, Brazil.
Federal University of Triângulo Mineiro. Department of Internal Medicine. Discipline of Infectious and Parasitic Diseases. Uberaba, MG, Brazil.
Hospital de Infecciosas. Buenos Aires, Argentina / Universidad Buenos Aires. Facultad de Medicina. Asignatura Enfermedades Infecciosas. Departamento de Medicina. Buenos Aires, Argentina.
Health Ministry. Health Surveillance Secretary. Evandro Chagas Institute. Belém, PA, Brazil.
Universidad Austral de Chile. Facultad de Medicina. Valdivia, Chile.
Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital. Department of Infectious Diseases. Barcelona, Spain.
ISGlobal. Universitat de Barcelona. Hospital Clínic. Barcelona, Spain.
World Health Organization. WHO Technical Group IVb on prevention, control and management of non congenital infections of the Global Network for Chagas Disease Elimination. Geneva, Switzerland / World Health Organization. Department of Control of Neglected Tropical Diseases. Geneva, Switzerland.
World Health Organization. Pan American Health Organization. Brasília, DF, Brazil.
Federal University of Ceará. School of Medicine. Department of Community Health. Fortaleza, CE, Brazil.
State University of Campinas. Faculty of Medical Sciences. Department of Internal Medicine. Campinas, SP, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Division of Infectious Diseases. São Paulo, SP, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Division of Infectious Diseases. São Paulo, SP, Brazil.
Ribeirão Preto Medical School University of São Paulo. Department of Internal Medicine. Division of Infectious Diseases. Ribeirão Preto, SP, Brazil.
Federal University of Triângulo Mineiro. Department of Internal Medicine. Discipline of Infectious and Parasitic Diseases. Uberaba, MG, Brazil.
University of Brasilia. School of Medicine. Centre for Tropical Medicine. Brasília, DF, Brazil.
Federal University of Health Sciences of Porto Alegre. Porto Alegre, RS, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Hospital de Infecciosas. Buenos Aires, Argentina / Health Ministry. National Institute of Parasitology. Departament of Clinics, Pathology and Treatment. Buenos Aires, Argentina.
Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital. Department of Infectious Diseases. Barcelona, Spain.
ISGlobal. Universitat de Barcelona. Hospital Clínic. Barcelona, Spain.
Ribeirão Preto Medical School University of São Paulo. Department of Internal Medicine. Division of Infectious Diseases. Ribeirão Preto, SP, Brazil.
Federal University of Triângulo Mineiro. Department of Internal Medicine. Discipline of Infectious and Parasitic Diseases. Uberaba, MG, Brazil.
Hospital de Infecciosas. Buenos Aires, Argentina / Universidad Buenos Aires. Facultad de Medicina. Asignatura Enfermedades Infecciosas. Departamento de Medicina. Buenos Aires, Argentina.
Health Ministry. Health Surveillance Secretary. Evandro Chagas Institute. Belém, PA, Brazil.
Universidad Austral de Chile. Facultad de Medicina. Valdivia, Chile.
Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital. Department of Infectious Diseases. Barcelona, Spain.
ISGlobal. Universitat de Barcelona. Hospital Clínic. Barcelona, Spain.
World Health Organization. WHO Technical Group IVb on prevention, control and management of non congenital infections of the Global Network for Chagas Disease Elimination. Geneva, Switzerland / World Health Organization. Department of Control of Neglected Tropical Diseases. Geneva, Switzerland.
World Health Organization. Pan American Health Organization. Brasília, DF, Brazil.
Federal University of Ceará. School of Medicine. Department of Community Health. Fortaleza, CE, Brazil.
State University of Campinas. Faculty of Medical Sciences. Department of Internal Medicine. Campinas, SP, Brazil.
Resumo em Inglês
Objective: Chagas disease (CD) globalization facilitated the co-infection with Human Immunodeficiency Virus (HIV) in endemic and non-endemic areas. Considering the underestimation of Trypanosoma cruzi (T. cruzi)-HIV co-infection and the risk of life-threatening Chagas Disease Reactivation (CDR), this study aimed to analyze the major co-infection clinical characteristics and its mortality rates.
Methods: This is a cross-sectional retrospective multicenter study of patients with CD confirmed by two serological or one parasitological tests, and HIV infection confirmed by immunoblot. CDR was diagnosed by direct microscopy with detection of trypomastigote forms in the blood or other biological fluids and/or amastigote forms in inflammatory lesions.
Results: Out of 241 patients with co-infection, 86.7% were from Brazil, 47.5% had <200 CD4+ T cells/μL and median viral load was 17,000 copies/μL. Sixty CDR cases were observed. Death was more frequent in patients with reactivation and was mainly caused by CDR. Other causes of death unrelated to CDR were the manifestation of opportunistic infections in those with Acquired Immunodeficiency Syndrome. The time between the co-infection diagnosis to death was shorter in patients with CDR. Lower CD4+ cells count at co-infection diagnosis was independently associated with reactivation. Similarly, lower CD4+ cells numbers at co-infection diagnosis and male sex were associated with higher lethality in CDR. Additionally, CD4+ cells were lower in meningoencephalitis than in myocarditis and milder forms.
Conclusion: This study showed major features on T. cruzi-HIV co-infection and highlighted the prognostic role of CD4+ cells for reactivation and mortality. Since lethality was high in meningoencephalitis and all untreated patients died shortly after the diagnosis, early diagnosis, immediate antiparasitic treatment, patient follow-up and epidemiological surveillance are essentials in T. cruzi/HIV co-infection and CDR managements.
Palavras-chave em inglês
Co-infectionsHIV diagnosis and management
Trypanosoma cruzi
Meningoencephalitis
Antiparasitic therapy
Parasitic diseases
HIV infections
Chagas disease
Compartilhar